Targeting Prenylated RAS Modifying Enzymes in Cancer Cells

Publisher： Bentham Science Publishers

E-ISSN： 2212-389x|1|3|285-293

ISSN： 1574-3624

Source： Current Signal Transduction Therapy, Vol.1, Iss.3, 2006-09, pp. : 285-293

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumour‐selective targeting of drug metabolizing enzymes to treat metastatic cancer

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 173, Iss. 19, 2016-10 ,pp. : 2811-2818

John Wiley & Sons Inc

Access to resources Recommend Favorite

National Cancer Institute focuses on RAS: Effort aims for better understanding, targeting of genes

By  

CANCER, Vol. 120, Iss. 4, 2014-02 ,pp. : 457-458

John Wiley & Sons Inc

Access to resources Recommend Favorite

MicroRNA‐Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer

By  

DRUG DEVELOPMENT RESEARCH, Vol. 76, Iss. 6, 2015-09 ,pp. : 328-342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recent Developments in Targeting Breast Cancer Stem Cells

By  

Recent Patents on Regenerative Medicine, Vol. 1, Iss. 1, 2011-01 ,pp. : 1-18

Bentham Science Publishers

Access to resources Recommend Favorite

Chimeric T-Cell Receptors for the Targeting of Cancer Cells

By  

Acta Haematologica, Vol. 110, Iss. 2-3, 2003-10 ,pp. : 154-159

Karger

Access to resources Recommend Favorite